Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1532MR)

This product GTTS-WQ1532MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1532MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14403MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ6314MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ10516MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ11428MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ9245MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10342MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ9366MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ2955MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW